JAMA Most Read http://www.elizeaboutbeauty.com/journals/jama The Most Read articles published by JAMA en-us Mon, 19 Apr 2021 13:43:29 GMT Mon, 19 Apr 2021 13:43:29 GMT Silverchair jamams@jamanetwork.org support@www.elizeaboutbeauty.com Figuring Out Whether COVID-19 Vaccines Protect Against Variants http://www.elizeaboutbeauty.com/journals/jama/fullarticle/2777785 Tue, 06 Apr 2021 00:00:00 GMT Rubin R. This Medical News feature examines what is known about the efficacy of COVID-19 vaccines against SARS-CoV-2 variants. 325 13 1241 1243 10.1001/jama.2021.3370 2777785 Neutralizing Antibodies Against SARS-CoV-2 Variants After Infection and Vaccination http://www.elizeaboutbeauty.com/journals/jama/fullarticle/2777898 Fri, 19 Mar 2021 00:00:00 GMT Edara V, Hudson WH, Xie X, et al. This study examines the neutralizing antibody response to 4 SARS-CoV-2 variants in infected and vaccinated individuals. 10.1001/jama.2021.4388 2777898 The Leading Causes of Death in the US for 2020 http://www.elizeaboutbeauty.com/journals/jama/fullarticle/2778234 Wed, 31 Mar 2021 00:00:00 GMT Ahmad FB, Anderson RN. This Viewpoint from the US National Center for Health Statistics reports a 2020 mortality estimate 17.7% higher than that of 2019, with leading causes of death comprising heart disease, cancer, and COVID-19. 10.1001/jama.2021.5469 2778234 Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19 http://www.elizeaboutbeauty.com/journals/jama/fullarticle/2777389 Tue, 13 Apr 2021 00:00:00 GMT LŮQpez-Medina E, LŮQpez P, Hurtado IC, et al. This randomized trial compares the effects of ivermectin vs placebo on time to symptom resolution within 21 days among patients with mild COVID-19. 325 14 1426 1435 10.1001/jama.2021.3071 2777389 Adverse Reactions in the US to mRNA-Based Coronavirus Vaccines http://www.elizeaboutbeauty.com/journals/jama/fullarticle/2778441 Mon, 05 Apr 2021 00:00:00 GMT Chapin-Bardales J, Gee J, Myers T. This JAMA Insights Clinical Update summarizes adverse reactions to the Pfizer-BioNTech and Moderna mRNA-based COVID-19 vaccines reported through February 2021 to the CDC’s new v-safe surveillance system, which collects near–real-time data via smartphone text message prompts and web-based health surveys. 10.1001/jama.2021.5374 2778441 Effect of Intermediate- vs Standard-Dose Anticoagulation on Outcomes of Patients With COVID-19 http://www.elizeaboutbeauty.com/journals/jama/fullarticle/2777829 Thu, 18 Mar 2021 00:00:00 GMT , Sadeghipour P, Talasaz AH, et al. This randomized trial compares the effect of intermediate-dose vs standard prophylactic enoxaparin on a composite outcome of acute venous thromboembolism (VTE), arterial thrombosis, need for extracorporeal membrane oxygenation (ECMO), and all-cause mortality within 30 days among patients with COVID-19 admitted to the ICU. 10.1001/jama.2021.4152 2777829 SARS-CoV-2–Specific Antibodies in Breast Milk After COVID-19 Vaccination of Breastfeeding Women http://www.elizeaboutbeauty.com/journals/jama/fullarticle/2778766 Mon, 12 Apr 2021 00:00:00 GMT Perl S, Uzan-Yulzari A, Klainer H, et al. This prospective study investigated whether antibodies from SARS-CoV-2 immunization of nursing mothers transferred to infants as a potentially protective effect. 10.1001/jama.2021.5782 2778766 Patient Information: Necessity of 2 Doses of the Pfizer and Moderna COVID-19 Vaccines http://www.elizeaboutbeauty.com/journals/jama/fullarticle/2776229 Tue, 02 Mar 2021 00:00:00 GMT Livingston EH. This JAMA Patient Page describes how the new Pfizer and Moderna COVID-19 vaccines available in the US work and explains why 2 doses of these vaccines are needed to confer adequate immunity. 325 9 898 898 10.1001/jama.2021.1375 2776229 Immunogenicity of a Single Dose of SARS-CoV-2 mRNA Vaccine in Solid Organ Transplant Recipients http://www.elizeaboutbeauty.com/journals/jama/fullarticle/2777685 Mon, 15 Mar 2021 00:00:00 GMT Boyarsky BJ, Werbel WA, Avery RK, et al. This study quantifies antispike protein antibody responses to first-dose messenger RNA (mRNA) COVID-19 vaccines in solid organ transplant recipients to better understand the immunogenicity of the vaccines in immunocompromised individuals. 10.1001/jama.2021.4385 2777685 Effect of Helmet Ventilation vs High-Flow Nasal Oxygen on Need for COVID-19 Respiratory Support http://www.elizeaboutbeauty.com/journals/jama/fullarticle/2778088 Thu, 25 Mar 2021 00:00:00 GMT Grieco D, Menga LS, Cesarano M, et al. This randomized trial compares the effects of helmet noninvasive ventilation (â‰?8 hours) followed by high-flow nasal oxygen (HFNO) vs HFNO alone on the number of days free of respiratory support at 28 days among patients with COVID-19 and moderate to severe hypoxemia. 10.1001/jama.2021.4682 2778088 Excess Deaths From COVID-19 and Other Causes in the US, March 2020 to January 2021 http://www.elizeaboutbeauty.com/journals/jama/fullarticle/2778361 Fri, 02 Apr 2021 00:00:00 GMT Woolf SH, Chapman DA, Sabo RT, et al. This study updates an analysis of US mortality in 2020, including deaths due to COVID-19 as well as all other causes. 10.1001/jama.2021.5199 2778361 Patient Information: The Johnson & Johnson Vaccine for COVID-19 http://www.elizeaboutbeauty.com/journals/jama/fullarticle/2777172 Mon, 01 Mar 2021 00:00:00 GMT Livingston EH, Malani PN, Creech C. This JAMA Patient Page explains how the Johnson & Johnson COVID-19 vaccine, likely to be the third SARS-CoV-2 vaccine approved for widespread use, uses an adenovirus 26 vector to deliver coronavirus DNA to host cells to produce spike proteins and safely and effectively induce immunity. 10.1001/jama.2021.2927 2777172 SARS-CoV-2 Vaccines—An Overview http://www.elizeaboutbeauty.com/journals/jama/fullarticle/2777059 Tue, 06 Apr 2021 00:00:00 GMT Creech C, Walker SC, Samuels RJ. This JAMA Insights clinical review explains different approaches to SARS-CoV-2 vaccine development, including inactivated and protein subunit, viral vector, and mRNA immunization strategies, and summarizes safety and efficacy data for global products authorized for use or in later-stage clinical trials. 325 13 1318 1320 10.1001/jama.2021.3199 2777059 Symptoms and Functional Impairment Among Health Care Workers 8 Months After Mild COVID-19 http://www.elizeaboutbeauty.com/journals/jama/fullarticle/2778528 Wed, 07 Apr 2021 00:00:00 GMT Havervall S, Rosell A, Phillipson M, et al. This cohort study describes COVID-19–related symptoms persisting 8 months after SARS-CoV-2 infection among Swedish health care workers and self-reported effects of the residual symptoms on respondentsâ€?home, work, and social function. 10.1001/jama.2021.5612 2778528 Acute Allergic Reactions to mRNA COVID-19 Vaccines http://www.elizeaboutbeauty.com/journals/jama/fullarticle/2777417 Mon, 08 Mar 2021 00:00:00 GMT Blumenthal KG, Robinson LB, Camargo CA, Jr, et al. This study examines the incidence of acute allergic reactions to mRNA COVID-19 vaccine administrations in health care employees in Massachusetts. 10.1001/jama.2021.3976 2777417 Effectiveness of Mask Wearing to Control Community Spread of SARS-CoV-2 http://www.elizeaboutbeauty.com/journals/jama/fullarticle/2776536 Tue, 09 Mar 2021 00:00:00 GMT Brooks JT, Butler JC. This JAMA Insights CDC review summarizes accumulating evidence that mask wearing reduces spread of SARS-CoV-2 infection and that universal mandatory mask wearing policies reduce infections and deaths and emphasizes face masks are one component of pandemic control measures, including physical distancing and handwashing, pending natural or vaccine-induced population immunity. 325 10 998 999 10.1001/jama.2021.1505 2776536 Effect of Weekly Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity http://www.elizeaboutbeauty.com/journals/jama/fullarticle/2777886 Tue, 13 Apr 2021 00:00:00 GMT Rubino D, Abrahamsson N, Davies M, et al. This randomized trial compares the effects of continuing weekly treatment with subcutaneous semaglutide vs switching to placebo on change in body weight over 48 weeks among adults with overweight or obesity who completed a 20-week run-in period with semaglutide. 325 14 1414 1425 10.1001/jama.2021.3224 2777886 Evaluation of Aducanumab for Alzheimer Disease http://www.elizeaboutbeauty.com/journals/jama/fullarticle/2778191 Tue, 30 Mar 2021 00:00:00 GMT Alexander G, Emerson S, Kesselheim AS. This Viewpoint details the development and regulatory path of aducanumab, a human IgG1 monoclonal antibody to treat Alzheimer disease, including termination of 2 clinical trials, identification of conflicting evidence of efficacy, and the FDA advisory committee vote against approval (final decision pending). 10.1001/jama.2021.3854 2778191 Anaphylaxis After Vaccination for COVID-19 in the US http://www.elizeaboutbeauty.com/journals/jama/fullarticle/2776557 Tue, 16 Mar 2021 00:00:00 GMT Shimabukuro TT, Cole M, Su JR. This JAMA Insights review provides clinical details of anaphylactic reactions reported to and verified by the CDC in the first month of use of the Pfizer-BioNTech and Moderna COVID-19 vaccines in the US, December 14, 2020-January 18, 2021. 325 11 1101 1102 10.1001/jama.2021.1967 2776557 Association of Convalescent Plasma Treatment With Clinical Outcomes in Patients With COVID-19 http://www.elizeaboutbeauty.com/journals/jama/fullarticle/2777060 Tue, 23 Mar 2021 00:00:00 GMT Janiaud P, Axfors C, Schmitt AM, et al. This meta-analysis of randomized trials reported in medical journals, preprint servers, and press releases estimates associations between convalescent plasma treatment and clinical outcomes (all-cause mortality, length of stay, clinical improvement, clinical deterioration, mechanical ventilation use, serious adverse events) in patients with COVID-19. 325 12 1185 1195 10.1001/jama.2021.2747 2777060 Effect of a Single High Dose of Vitamin D 3 in Patients With Moderate to Severe COVID-19 http://www.elizeaboutbeauty.com/journals/jama/fullarticle/2776738 Tue, 16 Mar 2021 00:00:00 GMT Murai IH, Fernandes AL, Sales LP, et al. This randomized trial compares the effects of a single 200â€?00-IU dose of vitamin D3 vs placebo on length of stay in patients hospitalized with moderate to severe COVID-19. 325 11 1053 1060 10.1001/jama.2020.26848 2776738 Low- vs High-Intensity Walking Exercise and Walk Distance in Patients With Peripheral Artery Disease http://www.elizeaboutbeauty.com/journals/jama/fullarticle/2778112 Tue, 06 Apr 2021 00:00:00 GMT McDermott MM, Spring B, Tian L, et al. This randomized trial compares the effects of comfortable low-intensity home-based walking exercise vs high-intensity exercise sufficient to elicit ischemic symptoms vs nonexercise control on 6-minute walk distance among patients with peripheral arterial disease (PAD). 325 13 1266 1276 10.1001/jama.2021.2536 2778112 Indoor Air Changes and Potential Implications for SARS-CoV-2 Transmission http://www.elizeaboutbeauty.com/journals/jama/fullarticle/2779062 Fri, 16 Apr 2021 00:00:00 GMT Allen JG, Ibrahim AM. This JAMA Insights review summarizes basic measures of indoor air ventilation as a means to explain how increases in frequency of air exchange and filtration capture efficiency could mitigate far-field airborne transmission of SARS-CoV-2 inside rooms and buildings. 10.1001/jama.2021.5053 2779062 Diagnosis and Management of Transient Ischemic Attack and Acute Ischemic Stroke http://www.elizeaboutbeauty.com/journals/jama/fullarticle/2777474 Tue, 16 Mar 2021 00:00:00 GMT Mendelson SJ, Prabhakaran S. This narrative review provides an update on management of transient ischemic attack (TIA) and acute ischemic stroke, emphasizing advances in use of dual antiplatelet therapy and fibrinolysis vs mechanical thrombectomy for secondary and tertiary prevention. 325 11 1088 1098 10.1001/jama.2020.26867 2777474 Vitamin D 3 to Treat COVID-19 http://www.elizeaboutbeauty.com/journals/jama/fullarticle/2776736 Tue, 16 Mar 2021 00:00:00 GMT Leaf DE, Ginde AA. Biological activity of vitamin D and its metabolites include, among other properties, potent antimicrobial and anti-inflammatory effects in vitro. In animal models, administration of vitamin D metabolites attenuates a variety of acute organ dysfunction, including acute lung injury. Observational data from patient cohorts support the potential therapeutic application of these findings. Specifically, lower circulating levels of vitamin D metabolites are independently associated with worse outcomes in patients with acute illness, including patients with coronavirus disease 2019 (COVID-19). 325 11 1047 1048 10.1001/jama.2020.26850 2776736 4887王中王鉄算 盘开奖结果小说